Avantor Inc.

Most of its revenue comes from selling physical products under individual purchase orders, recognized when goods are delivered rather than earned gradually over a contract term; a smaller part comes from services and custom manufacturing work billed as the work is performed. The company describes most of this revenue as recurring in nature, meaning customers tend to buy from it again and again, even though the underlying orders do not commit customers to any minimum quantity or future purchase.

Its overall earnings have not stayed positive every year: the most recent results on record show a net loss rather than a profit. Reaching a large operating scale has not, by itself, produced steady profitability.

Its inputs trace back to a single upstream industry. Beyond that broad classification, its own account describes drawing raw materials, chemical ingredients and components from a very large number of suppliers spread around the world. Some specific inputs, including active pharmaceutical ingredients and certain excipients, are described as sourced from only one or a few suppliers, so the exposure sits in particular materials rather than in the overall size of its supplier base. It also depends on retaining skilled employees, on its information and planning systems working reliably, and on currency conditions, especially the euro, because a large part of its operations and borrowing sit outside the United States.

It supplies several other industries downstream. Its own account describes a wide customer base spanning university and government research labs, private foundations, pharmaceutical and biotechnology companies, healthcare providers, medical device makers, and industrial and semiconductor manufacturers. By its own account, no single customer accounts for a meaningful share of its total sales, so what depends on it is a large, spread-out set of research, healthcare, government and industrial buyers rather than any one dominant customer.

The way this company turns raw inputs into finished products through its own manufacturing operations is a production model shared by a very large number of other companies. On the evidence available, this way of organizing production is common rather than rare, and nothing available shows whether any single part of its operation is something rivals specifically cannot replicate.

By its own account, it sells mostly through individual purchase orders with no minimum quantities or fixed commitments, so customers are not bound by long-term contracts in the usual sense. At the same time, it says its materials often become built into customers' approved manufacturing processes, which operate under strict technical and regulatory requirements, and that a large share of its revenue comes from customers it has served for a very long time. Together, this suggests that where switching away is hard, the difficulty comes from the cost and risk of re-qualifying a regulated manufacturing process, not from contractual lock-in.

By its own account, what caps how much it can sell is not only customer demand: it names the availability of raw materials, having enough manufacturing capacity running at the needed rate, clearing the regulatory approvals its products require, and recruiting and keeping skilled employees as direct limits on growth. It also states that when government funding for research is reduced or delayed, its customers buy less. This is the company's own description of its limits, not an outside measurement of which one binds hardest.

In its own risk disclosures, the risks it presents first are a serious interruption to its operations, constraints or inflation in its supply chain, and competition in markets it calls highly competitive. This is the order and emphasis the company itself gives its risks in its own filings, not a measurement CompanyGraph has independently verified or ranked.

By its own account, it operates under the oversight of multiple national health, safety, environmental and trade regulators across the countries where it works, and it is registered to handle goods controlled under arms-export rules. It discloses that it is a defendant in securities-related lawsuits, that an environmental regulator has ordered remediation work at one of its manufacturing sites, and that tariffs, sanctions and changing trade or export rules can alter its costs and sourcing. A meaningful part of its financial results is also exposed to foreign currency movements, particularly the euro, reflecting how much of its operations and borrowing sit outside the United States.